
Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Pulmatrix Corporate Overview (2018.08) – final for website
Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Pulmatrix Corporate Overview (2018.08) – final for website
VANCOUVER, Washington, March 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), […]
VANCOUVER, Washington, Jan. 13, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]
VANCOUVER, Washington, June 14, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications announced today that it […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.